5 news items
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
IVVD
7 May 24
and adequate reimbursement for PEMGARDA or any other product candidate; the company's ability to leverage its INVYMAB platform approach to facilitate the rapid
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
IVVD
15 Apr 24
-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product
Invivyd Announces CEO Transition
IVVD
12 Apr 24
and maintain third-party coverage and adequate reimbursement for PEMGARDA or any other product candidate; the company's ability to leverage its INVYMAB
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
IVVD
4 Apr 24
and maintain third-party coverage and adequate reimbursement for PEMGARDA or any other product candidate; the company's ability to leverage its INVYMAB
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
IVVD
22 Mar 24
the company can obtain and maintain third-party coverage and adequate reimbursement for PEMGARDA or any other product candidate; the company's ability
- Prev
- 1
- Next